Does tocilizumab mean the end of glucocorticoids in giant cell arteritis?

被引：1
|
作者：
Samson, M. [1 ,2 ,3 ]
Bonnotte, B. [1 ,2 ,3 ]
机构：
[1] CHU Dijon Bourgogne, Serv Med Interne, 2 Blvd Mal de Lattre de Tassigny, F-21000 Dijon, France
[2] CHU Dijon Bourgogne, Immunol Clin, 2 Blvd Mal de Lattre de Tassigny, F-21000 Dijon, France
[3] Univ Bourgogne Franche Comte, FHU Increase, Inserm U1098, F-21000 Dijon, France
来源：
REVUE DE MEDECINE INTERNE | 2018年 / 39卷 / 02期
关键词：
Giant cell arteritis; Treatment; Tocilizumab; LARGE-VESSEL VASCULITIS; TAKAYASU ARTERITIS; DOUBLE-BLIND; THERAPY; TRIAL; ABATACEPT;
D O I：
10.1016/j.revmed.2017.11.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：75 / 77
页数：3
相关论文
共 50 条
  • [1] Tocilizumab in Giant Cell Arteritis
    Mariano, Vincent J.
    Frishman, William H.
    CARDIOLOGY IN REVIEW, 2018, 26 (06) : 321 - 330
  • [2] Tocilizumab in the treatment of giant cell arteritis
    Leuchten, Nicolai
    Aringer, Martin
    IMMUNOTHERAPY, 2018, 10 (06) : 465 - 472
  • [3] Tocilizumab and glucocorticoids for giant cell arteritis: the learning curve
    Mackie, Sarah L.
    Bhogal, Rayna
    LANCET RHEUMATOLOGY, 2023, 5 (12) : e703 - e705
  • [4] Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis
    Matteson, Eric L.
    Buttgereit, Frank
    Dejaco, Christian
    Dasgupta, Bhaskar
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2016, 42 (01) : 75 - +
  • [5] Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study
    Samson, Maxime
    Devilliers, Herve
    Ly, Kim Heang
    Maurier, Francois
    Bienvenu, Boris
    Terrier, Benjamin
    Charles, Pierre
    Guillevin, Loic
    Besancenot, Jean-Francois
    Liozon, Eric
    Fauchais, Anne Laure
    Loffroy, Romaric
    Binquet, Christine
    Audia, Sylvain
    Seror, Raphaele
    Mariette, Xavier
    Bonnotte, Bernard
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2018, 57 : 96 - 104
  • [6] Tocilizumab for the treatment of giant cell arteritis
    Schirmer, Michael
    Muratore, Francesco
    Salvarani, Carlo
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2018, 14 (05) : 339 - 349
  • [7] Tocilizumab in giant cell arteritis: an update for the clinician
    Ford, Julia A.
    Gewurz, Danya
    Gewurz-Singer, Ora
    CURRENT OPINION IN RHEUMATOLOGY, 2023, 35 (03) : 135 - 140
  • [8] Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
    Loricera, Javier
    Castaneda, Santos
    Moriano, Clara
    Narvaez, Javier
    Aldasoro, Vicente
    Maiz, Olga
    Melero, Rafael
    Villa, Ignacio
    Vela, Paloma
    Romero-Yuste, Susana
    Callejas, Jose L.
    de Miguel, Eugenio
    Galindez-Agirregoikoa, Eva
    Sivera, Francisca
    Fernandez-Lopez, Jesus C.
    Galisteo, Carles
    Ferraz-Amaro, Ivan
    Sanchez-Martin, Julio
    Sanchez-Bilbao, Lara
    Calderon-Goercke, Monica
    Casado, Alfonso
    Hernandez, Jose L.
    Gonzalez-Gay, Miguel A.
    Blanco, Ricardo
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2022, 14
  • [9] Tocilizumab for giant cell arteritis: an amazing result
    Isik, Metin
    Kilic, Levent
    Dogan, Ismail
    Calguneri, Meral
    RHEUMATOLOGY INTERNATIONAL, 2013, 33 (11) : 2961 - 2962
  • [10] Treatment of giant cell arteritis
    Sailler, L.
    Pugnet, G.
    Bienvenu, B.
    REVUE DE MEDECINE INTERNE, 2013, 34 (07): : 431 - 437
12345